<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125577</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-17005</org_study_id>
    <nct_id>NCT03125577</nct_id>
  </id_info>
  <brief_title>Combination CAR-T Cell Therapy Targeting Hematological Malignancies</brief_title>
  <official_title>Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate safety and efficacy of a combination of 4th generation chimeric&#xD;
      antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22&#xD;
      (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients&#xD;
      with B cell malignancies. Clinical response and development of a standardized lentiviral&#xD;
      vector and cell production protocol will be investigated. This is a phase I/II trial&#xD;
      enrolling patients from multiple clinical centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      T cells modified with lentiviral chimeric antigen receptor (CAR) gene have been studied in&#xD;
      different clinical settings. Recent successes suggest that increased costimulatory signaling&#xD;
      in the CAR design is critical for long term efficacy. Several clinical reports indicate that&#xD;
      many patients still relapse and developed CD19-negative cancer cells after CD19 targeted&#xD;
      therapy. Thus, to prevent the target escapes and improve the therapeutic effects, CAR&#xD;
      gene-modified T cells targeting CD20, CD22, CD30, CD38, CD70 or CD123 are considered to apply&#xD;
      together with CD19 CAR-T cells.&#xD;
&#xD;
      Activation of T cell response to high tumor burden may induce a severe response. To increase&#xD;
      safety, a novel design using an inducible caspase 9 fusion gene has been incorporated in the&#xD;
      CAR gene. A 4th generation CAR lentiviral vector (4SCAR) carrying multiple costimulatory&#xD;
      signals for CD28/CD137/CD27 plus an inducible apoptotic caspase 9 gene has been established.&#xD;
      This study aims to evaluate the activities of a combination of CAR gene-modified T cells to&#xD;
      target cancer cells based on specific CD19/CD20/CD22/CD30/CD38/CD70/CD123 single chain&#xD;
      antibody gene designs (4SCAR19/20/22/30/38/70/123).&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To evaluate safety and efficacy of administrating 4SCAR19, 4SCAR20, 4SCAR22, 4SCAR30,&#xD;
      4SCAR38, 4SCAR70 and 4SCAR123 T cells to patients with mixed CD19 positive and negative B&#xD;
      cell malignancies following a cyclophosphamide/fludarabine based conditioning regimen.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients older than 6-month-old with CD19 positive or negative B cell malignancies that have&#xD;
      recurred after or refractory to standard therapy and is deemed incurable using standard&#xD;
      treatment.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened based on cancer cell phenotype analyzed using flow cytometry or&#xD;
      immunohistochemical staining methods. Peripheral blood mononuclear cells (PBMC) will be&#xD;
      obtained through apheresis. On Day -5 to -7, T cells from PBMC will be activated and&#xD;
      enriched, which will be followed by 4SCAR19, 4SCAR20, 4SCAR22, 4SCAR30, 4SCAR38, 4SCAR70 and&#xD;
      4SCAR123 lentiviral transduction. The total cell preparation time is approximately 5-7 days.&#xD;
      Participants will receive a preparative conditioning regimen comprising&#xD;
      cyclophosphamide/fludarabine to prepare their immune system to accommodate the modified CAR T&#xD;
      cells. The preparative regimen will depend on the immune condition of patients, which is&#xD;
      consistent with standard chemotherapy conditioning regimen. Participants will receive an&#xD;
      infusion of the modified 4SCAR19 and 4SCAR20/22/30/38/70/123 T cells and closely followed up&#xD;
      for treatment-related responses. Participants will be continuously monitored for CAR T cells&#xD;
      and clinical responses in a preset timeline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of fourth generation anti CD19 and CD20/CD22/CD30/CD38/CD70/CD123 CAR-T cells in patients with relapsed B cell malignancies using CTCAE 4 standard to evaluate the level of adverse events standard to evaluate the level of adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>physiological parameter (for safety, measuring cytokine response, fever, symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti tumor activity of fourth generation anti CD19 and CD20/CD22/CD30/CD38/CD70/CD123 CAR-T cells in patients with relapsed or refractory B cell malignancies</measure>
    <time_frame>1 year</time_frame>
    <description>scale of CAR copies and leukemic cell burden (for efficacy)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4SCAR19 and 4SCAR22</intervention_name>
    <description>4SCAR19 and 4SCAR22</description>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4SCAR19 and 4SCAR38</intervention_name>
    <description>4SCAR19 and 4SCAR38</description>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4SCAR19 and 4SCAR20</intervention_name>
    <description>4SCAR19 and 4SCAR20</description>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4SCAR19 and 4SCAR123</intervention_name>
    <description>4SCAR19 and 4SCAR123</description>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4SCAR19 and 4SCAR70</intervention_name>
    <description>4SCAR19 and 4SCAR70</description>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4SCAR19 and 4SCAR30</intervention_name>
    <description>4SCAR19 and 4SCAR30</description>
    <arm_group_label>4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age older than 6 months.&#xD;
&#xD;
          2. malignant B cell surface expression of CD19/CD20/CD22/CD30/CD38/CD70/CD123 molecules.&#xD;
&#xD;
          3. the KPS score over 80 points, and survival time is more than 1 month.&#xD;
&#xD;
          4. greater than Hgb 80 g/L.&#xD;
&#xD;
          5. no contraindications to blood cell collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. accompanied with other active diseases, the treatment is difficult to assess patient&#xD;
             response.&#xD;
&#xD;
          2. bacteria, fungus, or virus infection, unable to control.&#xD;
&#xD;
          3. living with HIV.&#xD;
&#xD;
          4. active HBV and HCV infection.&#xD;
&#xD;
          5. pregnant and nursing mothers.&#xD;
&#xD;
          6. under systemic steroid treatment within a week of the treatment.&#xD;
&#xD;
          7. prior failed CAR-T treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Geno-Immune Medical Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <phone>+86-0755 8672-5195</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhua Li, M.D, Ph.D</last_name>
      <phone>86-13533706656</phone>
      <email>liyuhua2011gz@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Yang, M.D., Ph.D.</last_name>
      <phone>+86-13580532469</phone>
      <email>dryanglihua@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Geno-immune Medical Institute</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Ji Chang, PhD</last_name>
      <phone>86-13671121909</phone>
      <email>c@szgimi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University &amp; Yunnan Cancer Center</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xun Lai, MD</last_name>
      <phone>86-13577096609</phone>
      <email>1729112214@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Geno-Immune Medical Institute</investigator_affiliation>
    <investigator_full_name>Lung-Ji Chang</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>4S CAR-T</keyword>
  <keyword>CD19</keyword>
  <keyword>CD20</keyword>
  <keyword>CD22</keyword>
  <keyword>CD38</keyword>
  <keyword>CD123</keyword>
  <keyword>B cell leukemia</keyword>
  <keyword>B-ALL</keyword>
  <keyword>CD70</keyword>
  <keyword>CD30</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

